Posted: 10 February 2025
INOVIQ Limited (ASX:IIQ) is pleased to announce the establishment of its Medical and Scientific Advisory Board (MSAB). The MSAB will provide world-class research expertise, clinical insight and strategic advice focusing on liquid biopsy diagnostics and targeted therapeutics for cancer. Its guidance will help steer INOVIQ’s key development milestones and clinical trials.
The MSAB comprises the following clinical researchers and oncologists:
- Professor H. Miles Prince AM: Leading Clinical Haematologist and Oncologist and Professor at both Melbourne and Monash universities. He is an NHMRC Investigator Fellow and has been principal investigator of over 100 clinical trials including targeted therapeutics (CAR-T therapy) for haematological conditions and cancers.
- Professor Phillip K. Darcy: Group Leader of the Cancer Immunotherapy Laboratory at the Peter MacCallum Cancer Centre and NHMRC Principal Research Fellow, focusing on novel T cell-based immunotherapy approaches for cancer in preclinical mouse models and clinical translation.
- Professor Carlos Salomon: Director of the University of Queensland Centre for Extracellular Vesicle Nanomedicine, Head of the Translational Extracellular Vesicles in Obstetrics and Gynae Oncology Group and NHMRC Investigator Fellow, specialising in exosome biology and its clinical translation to diagnostics and therapeutics for ovarian cancer and obstetrical syndromes
- Dr James McCracken: Leading Medical Oncologist specialising in breast cancer treatment at Epworth Healthcare and the Peter MacCallum Cancer Centre. His research interests include the field of liquid biopsies for cancer to personalise treatment and minimise toxicity.
Detailed profiles of the MSAB members are provided in the Appendices.
CEO Leearne Hinch said: “We are thrilled to welcome these high-calibre clinical researchers and oncologists to join our Advisory Board. Their expertise will be invaluable as we advance our next generation exosome diagnostics and therapeuticstowards the clinic. We look forward to working with the Advisory Board to guide our programs and deliver much-needed earlier diagnostics and more effective treatments for cancer.”
Chairman David Williams added: “I am looking forward to this Board adding depth and clinical expertise to our research of products. I encourage shareholders to read the detailed biographies below and the relevance of each to INOVIQ is obvious and exciting.”
